Management of patients with atrial fibrillation and chronic kidney disease in light of the latest guidelines

Polskie Archiwum Medycyny Wewnetrznej

Volumn 126, Issue 5, 2016, Pages 353-362

  Młodawska, Elzbieta ^a   Tomaszuk Kazberuk, Anna ^a   Łopatowska, Paulina ^a   Musial, Włodzimierz J ^a   Małyszko, Jolanta ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Anticoagulation; Atrial fibrillation; Kidney function; Stroke

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; DABIGATRAN; EDOXABAN; IDARUCIZUMAB; RIVAROXABAN; WARFARIN;

ALBUMINURIA; ANEMIA; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; EMERGENCY CARE; END STAGE RENAL DISEASE; GLOMERULUS FILTRATION RATE; HEMOSTASIS; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KIDNEY FUNCTION; LOW DRUG DOSE; PATIENT CARE; PRACTICE GUIDELINE; R2CHADS2 SCORE; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; THROMBIN TIME; COMPLICATION; DISEASE MANAGEMENT; FEMALE; MALE; RENAL INSUFFICIENCY, CHRONIC; STROKE; THROMBOSIS;

ANTICOAGULANTS; ATRIAL FIBRILLATION; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; RENAL INSUFFICIENCY, CHRONIC; STROKE; THROMBOSIS;

EID: 84978395250     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.3431     Document Type: Review

References (89)

1. Camm J, Lip GY, Caterina R, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J. 2012; 33: 2719-2747.
2. Camm J, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation. Eur Heart J. 2010; 31: 2369-2429.
3. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci Sl. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213-220.
4. Naghavi M, Wang H, Lozano R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study. Lancet. 2013; 385: 117-171.
5. Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011; 80: 572-586.
6. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol. 2005; 13: 181-193.
7. Wetmore JB, Mahnken JD, Rigler SK, et al. The prevalence of and factors associated with chronic atrial fibrillation in Medicare/Medicaid-eligible dialysis patients. Kidney Int. 2012; 81: 469-476.
8. Genovesi S, Pogliani D, Faini A, et al. Prevalence of atrial fibrillation and associated factors in a population of long-term hemodialysis patients. Am J Kidney Dis. 2005; 46: 897-902.
9. Soliman EZ, Prineas RJ, Go AS, et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010; 159: 1102-1107.
10. Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated with the incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2011; 123: 2946-2953.
11. Baber U, Howard VJ, Halperin JL, et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: Reasons for geographic and racial differences in stroke (REGARDS) study. Circ Arrhythm Electrophysiol. 2011; 4: 26-32.
12. Ananthapanyasut W, Napan S, Rudolph EH, et al. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease. Clin J Am Soc Nephrol. 2010; 5:173-181.
13. Suzuki S, Sagara K, Otsuka T, et al. Estimated glomerular filtration rate and proteinuria are associated with persistent form of atrial fibrillation: Analysis in Japanese patients. J Cardiol. 2013; 61: 53-57.
14. Wizemann V, Tong L, Satayathum S, et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 2010; 77: 1098-1106.
15. Fujii H, Kim JI, Yoshiya K, et al. Clinical characteristics and cardiovascular outcomes of hemodialysis patients with atrial fibrillation: A prospective follow-up study. Am J Nephrol. 2011; 34: 126-134.
16. Vázquez-Ruiz de Castroviejoa, E, Sánchez-Perales C, Lozano Cabezas C, et al. Incidence of atrial fibrillation in hemodialysis patients: A prospective long-term follow-up study. Rev Esp Cardiol. 2006; 59: 779-784.
17. Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients. Am J Kidney Dis. 2008; 51: 255-262.
18. Vazquez E, Sanchez-Perales C, Garcia-Garcia F, et al. Atrial fibrillation in incident dialysis patients. Kidney Int. 2009; 76: 324-330.
19. Goldstein BA, Arce CM, Hlatky MA, et al. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation. 2012; 126: 2293-2301.
20. Remppis A, Ritz E. Cardiac problems in the dialysis patient: beyond coronary disease. Semin Dial. 2008; 21: 319-325.
21. Grande A. Atrial fibrillation and dialysis. A convergence of risk factors. Rev Esp Cardiol. 2006; 59: 766-769.
22. Korantzopoulos P, Liu T, Li L, et al. Implantable cardioverter defibrillator therapy in chronic kidney disease: A meta-analysis. Europace. 2009; 11: 1469-1475.
23. Korantzopoulos P, Liu T, Letsas KP, et al. The epidemiology of atrial fibrillation in end-stage renal disease. J Nephrol. 2013; 26: 617-623.
24. Chou CY, Kuo HL, Wang SM, et al. Outcome of atrial fibrillation among patients with end-stage renal disease. Nephrol Dial Transplant. 2010; 25: 1225-1230.
25. Xu D, Murakoshi N, Sairenchi T, et al. Anemia and reduced kidney function as risk factors for new onset of atrial fibrillation (from the Ibaraki prefectural health study). Am J Cardiol. 2015; 115: 328-333.
26. Hirakata H, Tsubakihara Y, Gejyo F, et al. Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. Clin Exp Nephrol. 2010; 14: 28-35.
27. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: The Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015; 36: 297-306.
28. Reinecke H, Brand E, Mesters R, et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. J Am Soc Nephrol. 2009; 20: 705-711.
29. Nakagawa K, Hirai T, Takashima S, et al. Chronic kidney disease and CHADS(2) score independently predict cardiovascular events and mortality in patients with nonvalvular atrial fibrillation. Am J Cardiol. 2011; 107: 912-916.
30. Go AS, Fang MC, Udaltsova N, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Circulation. 2009; 119: 1363-1369.
31. Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367: 625-635.
32. U.S. Renal Data System (USRDS) 2006 Annual Data Report. Volume 2: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, 2006.
33. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA. 2001; 285: 2370-2375.
34. Bos MJ, Koudstaal PJ, Hofman A, Breteler MM. Decreased glomerular filtration rate is a risk factor for hemorrhagic but not for ischemic stroke: The Rotterdam study. Stroke. 2007; 38; 3127-3132.
35. Lip GY. Chronic renal disease and stroke in atrial fibrillation: balancing the prevention of thromboembolism and bleeding risk. Europace. 2011; 13: 145-148.
36. Mitsuma W, Matsubara T, Hatada K, et al. Clinical characteristics of hemodialysis patients with atrial fibrillation: The RAKUEN (Registry of atrial fibrillation in chronic kidney disease under hemodialysis from Niigata) study. J Cardiol. 2015; [Epub ahead of print].
37. Fu S, Liu T, Luo L, Ye P. Different types of atrial fibrillation, renal function, and mortality in elderly Chinese patients with coronary artery disease. Clin Interv Aging. 2014; 9: 301-308.
38. Bansal N, Fan D, Hsu CY, et al. Incident atrial fibrillation and risk of death in adults with chronic kidney disease. J Am Heart Assoc. 2014; 3: E001303.
39. Winkelmayer WC, Patrick AR, Liu J, et al. The increasing prevalence of atrial fibrillation among hemodialysis patients. J Am Soc Nephrol. 2011; 22: 349-357.
40. Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003; 24: 1231-1243.
41. Mlodawska E, Tomaszuk-Kazberuk A, Lopatowska P, et al. Is there association between changes in eGFR value and the risk of permanent type of atrial fibrillation? Analysis of valvular and non-valvular atrial fibrillation population. Kidney Blood Press Res. 2014; 39: 600-608.
42. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351: 1285-1295.
43. Bautista J, Bella A, Chaudhari A, et al. Advanced chronic kidney disease in non-valvular atrial fibrillation: Extending the utility of R2CHADS2 to patients with advanced renal failure. Clin Kidney J. 2015; 8: 226-231.
44. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013; 127: 224-232.
45. Mancuso, P, Antoniotti, P, Quarna, J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res. 2009; 15: 267-273.
46. Eberst E, Berkowitz LR. Hemostasis in renal disease: Pathophysiology and management. Am J Med. 1994; 96: 168-179.
47. Andrassy K. Kidney and haemostasis. A (personal) time-journey. Hamostaseologie. 2015; 35: 73-76.
48. Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014; 29: 29-40.
49. Jalal D, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost. 2010; 36: 34-40.
50. Małyszko J, Małyszko JS, Mysliwiec M, Buczko W. Hemostasis in chronic renal failure. Rocz Akad Med Bialymst. 2005; 50: 126-131.
51. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta. 2010; 411: 1412-1420.
52. Zeng WT, Sun XT, Tang K, et al. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease. Stroke. 2015; 46: 157-163.
53. King A. Atrial fibrillation: HAS-BLED-a new risk score to predict bleeding in patients with AF. Nat Rev Cardiol. 2011; 8: 64.
54. Hohnloser SH. Stroke prevention versus bleeding risk in atrial fibrillation: A clinical dilemma. J Am Coll Cardiol. 2011; 57: 181-183.
55. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
56. Connolly SJ, Paul Reilly, Cameron D. Joyner, et al. Effect of age and renal function on the risks of stroke and major bleeding with dabigatran compared to warfarin: An analysis from the RE-LY study. J Am Coll Cardiol. 2010; 55: A4.E37.
57. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban vs. warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
58. Goto S, Zhu J, Liu L, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014; 168: m303-m309.
59. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104.
60. Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17: 1467-1507.
61. Chatrou ML, Winckers K, Hackeng TM, et al. Vascular calcification: The price to pay for anticoagulation therapy with vitamin K-antagonists. Blood Rev. 2012; 26: 155-166.
62. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int. 2011; 80: 181-189.
63. Böhm M, Ezekowitz MD, Connolly SJ, et al. Changes in renal function in patients with atrial fibrillation. An analysis from the RE-LY Trial. J Am Coll Cardiol. 2015; 65: 2481-2493.
64. Maegdefessel L, Spin JM, Azuma J, Tsao PS. New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag. 2010; 6: 339-349.
65. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015; 373: 511-520.
66. Chai-Adisaksopha C, Hillis C, Lim W, et al. Hemodialysis for the treatment of dabigatran-associated bleeding: A case report and systematic review. J Thromb Haemost. 2015; 13: 1790-1798.
67. Husted S, Verheugt FW, Comuth WJ. Reversal Strategies for NOACs: State of development, possible clinical applications and future perspectives. Drug Saf. 2016; 39: 5-13.
68. Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012; 33: 2821-2830.
69. Pathak R, Pandit A, Karmacharya P, et al. Meta-analysis on risk of bleeding with apixaban in patients with renal impairment. Am J Cardiol. 2015; 115: 323-327.
70. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kidney Int. 1994; 46: 287-296.
71. Malyszko J, Malyszko JS, Kozminski P, et al. Adipokines, linking adipocytes and vascular function in hemodialyzed patients, may also be possibly related to CD146, a novel adhesion molecule. Clin Appl. Thromb Hemostas. 2008; 14: 338-345.
72. Małyszko J, Małyszko JS, Mysliwiec M. Comparison of hemostasis between CAPD and HD patients. Perit Dial Int. 2001; 21: 158-165.
73. Małyszko J, Małyszko JS, Mysliwiec M. Endothelial cell injury markers in chronic renal failure on conservative treatment and continuous ambulatory peritoneal dialysis (CAPD). Kidney Blood Press Res. 2004; 27: 71-77.
74. Malyszko J, Malyszko JS, Wolczynski S, et al. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab. 2004; 89: 4620-4627.
75. Adams MJ, Irish AB, Watts GF, et al. Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function. Thromb Res. 2008; 123: 374-380.
76. Chen JJ, Lin LY, Yang YH, et al. Anti-platelet or anti-coagulant agent for the prevention of ischemic stroke in patients with end-stage renal disease and atrial fibrillation-a nation-wide database analyses. Int J Cardiol. 2014; 177: 1008-1011.
77. Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014; 129: 1196-1203.
78. Chan PH, Huang D, Yip PS, et al. Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. Europace. 2015 Oct 15. pii: Euv289. [Epub ahead of print].
79. Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: The Swedish Atrial Fibrillation Cohort study. Eur Heart J. 2015; 36: 297-306.
80. Tanaka A, Inaguma D, Shinjo H, et al. Aichi Cohort Study of Prognosis in Patients Newly Initiated into Dialysis (AICOPP) Study Group. Presence of atrial fibrillation at the time of dialysis initiation is associated with mortality and cardiovascular events. Nephron. 2016; 132: 86-92.
81. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130: 2071-2104.
82. Schwartzenberg S, Lev EI, Sagie A, et al. The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. Am J Cardiol. 2016; 117: 477-482.
83. Lin TT, Chiang JY, Liao MT, et al. Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. Sci Rep. 2015; 5: 17731.
84. Food and Drug Administration. Guidance for industry: Pharmacokinetics in patients with impaired renal function-Study design, data analysis, and impact on dosing and labeling. US Department of Health and Human Services, Rockville, MD 1998. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072127.pdf. Accessed April 9, 2016.
85. Stevens LA, Nolin TD, Richardson MM. Chronic kidney disease epidemiology collaboration. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis. 2009; 54: 33-42.
86. NKDEP: CKD and Drug Dosing: Information for Providers. http://nkdep.nih.gov/resources/CKD-drug-dosing.shtml. Accessed April 9, 2016.
87. Lindhoff-Last E, Samama MM, Ortel TL, et al. Assays for measuring rivaroxaban: Their suitability and limitations. Ther Drug Monit. 2010; 32: 673-679.
88. Chronic kidney disease in adults: Assessment and management. NICE guidelines. http://www.nice.org.uk/guidance/cg182/chapter/1-recommendations#pharmacotherapy. Accessed March 11, 2016.
89. Kovacs RJ, Flaker GC, Saxonhouse SJ, et al. Practical management of anticoagulation in patients with atrial fibrillation. J Am Coll Cardiol. 2015; 65: 1340-1360.